The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Håkan Axelson

Håkan Axelson

Research team manager

Håkan Axelson

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.

Author

  • Sophie Lehn
  • Nicholas P Tobin
  • Andrew H Sims
  • Olle Stål
  • Karin Jirström
  • Håkan Axelson
  • Göran Landberg

Summary, in English

Yes-associated protein (YAP1) is frequently reported to function as an oncogene in many types of cancer, but in breast cancer results remain controversial. We set out to clarify the role of YAP1 in breast cancer by examining gene and protein expression in subgroups of patient material and by downregulating YAP1 in vitro and studying its role in response to the widely used anti-estrogen tamoxifen.

Department/s

  • Pathology, Malmö
  • Molecular Pathology, Malmö
  • Tumor microenvironment
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Division of Translational Cancer Research

Publishing year

2014

Language

English

Publication/Series

BMC Cancer

Volume

14

Issue

1

Document type

Journal article

Publisher

BioMed Central (BMC)

Topic

  • Cancer and Oncology

Status

Published

Research group

  • Pathology, Malmö
  • Molecular Pathology, Malmö

ISBN/ISSN/Other

  • ISSN: 1471-2407